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Human serum-derived protein removes the need
for coating in deﬁned human pluripotent stem cell
culture
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Reliable, scalable and time-efﬁcient culture methods are required to fully realize the clinical
and industrial applications of human pluripotent stem (hPS) cells. Here we present a
completely deﬁned, xeno-free medium that supports long-term propagation of hPS cells on
uncoated tissue culture plastic. The medium consists of the Essential 8 (E8) formulation
supplemented with inter-a-inhibitor (IaI), a human serum-derived protein, recently
demonstrated to activate key pluripotency pathways in mouse PS cells. IaI efﬁciently induces
attachment and long-term growth of both embryonic and induced hPS cell lines when added
as a soluble protein to the medium at seeding. IaI supplementation efﬁciently supports
adaptation of feeder-dependent hPS cells to xeno-free conditions, clonal growth as well as
single-cell survival in the absence of Rho-associated kinase inhibitor (ROCKi). This
time-efﬁcient and simpliﬁed culture method paves the way for large-scale, high-throughput
hPS cell culture, and will be valuable for both basic research and commercial applications.
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H
uman pluripotent stem (hPS) cells, including human
embryonic stem cells (hES cells) and induced pluripotent
stem cells (hiPS cells), can self-renew indeﬁnitely while
retaining the capacity to differentiate into any somatic cell type.
They therefore have great potential in various applications
including basic developmental research, drug/toxicity screening
and cell-based therapeutics1. The complex matrix requirements
of hPS cells, which make up the hPS cell ‘niche’, are well
documented and traditionally hPS cell expansion has necessitated
culture on feeder cells and serum-containing media2. However,
incompatibility of these complex, ill-deﬁned conditions with
pharmacological and medical applications has driven the
development of alternative strategies combining deﬁned media
with improved surfaces. Solutions typically include surface
immobilization of cell-binding motifs, such as integrin-binding
proteins3,4, short peptides derived from vitronectin (VN), laminin
(LN)5,6, glycosaminoglycan (GAG)-binding peptides6,7 and
synthetic polymers8,9. Current novel approaches use high-
throughput combinatorial arrays to discover fully synthetic
alternatives10. However, to date, these methods have not been
widely implemented, being either too expensive or lacking the
required reproducibility, leaving feeder cells or Matrigel11
in widespread use. Moreover, many hPS cell lines have also
proven resistant to successful adaptation to feeder-free
conditions. There are many hPS cell-speciﬁc issues that need to
be addressed for optimal culture. Routine culture usually involves
passage in small aggregates or clumps to avoid a loss of viability
associated with dissociation (anoikis). The addition of ROCKi
(Y-27632) to the hPS cell medium increases survival after
single-cell passaging, but it is costly, particularly at scale12.
Recent years have seen considerable efforts made to simplify and
reﬁne medium formulations, and the fully deﬁned E8 medium is
an important step forward in this regard5. Containing only eight
components, all of them produced recombinantly, E8 is typically
used together with a recombinant VN peptide which is pre-
applied to the tissue culture (TC) plastic as a coating for
optimal cell attachment and survival (the one used in this study is
Vitronectin-XF (VN-XF), distributed by Primorigen and
StemCell Technologies). The combination of E8 and VN-XF
has the beneﬁts of being xeno-free and deﬁned. However, as
shown in the present study, this method does not robustly
support cloning and single-cell passaging unless cells are pre-
treated for several hours with ROCKi. Large-scale and automated
systems of the future will require affordable reagents available in
large quantities, and simpliﬁed methodologies that can support
efﬁcient and reliable single-cell passaging.
The IaI protein family members are present at high
concentrations (0.6–1.2mgml 1) in human serum13. Inter-a-
inhibitor (IaI), which is the most common family member,
consists of two heavy chains (HC1 and HC2) and a bikunin
(Bk) domain linked together by chondroitin sulphate13,14. The
IaI complex has been associated to inﬂammation processes,
hepatitis, cancer and even kidney diseases15–19. Traditionally, IaI
has been described as an extracellular matrix (ECM) component.
The HCs are the only proteins known to covalently bind the
ECM GAG hyaluronan (HA), while Bk when released from
the HCs acts as a serine protease inhibitor14,20,21. However,
recent reports demonstrate that the HC domains can additionally
induce cell signalling20,22–24. Indeed, we recently showed that
IaI (speciﬁcally its HC2 domain) activates the Yes/Yes-associated
protein (YAP)/TEAD transcription factor pathway and induces
expression of Oct4 and Nanog in mouse ES (mES) cells24.
In the present study we demonstrate, for the ﬁrst time, that IaI
and its HC2 domain promote attachment and survival of hPS
cells. Moreover, we describe a new, simpliﬁed and time-efﬁcient
cell culture method based on the E8 medium supplemented with
soluble IaI (herein called E8:IaI). This method requires no
surface coating and supports long-term propagation of hPS
cells, clonal expansion and single-cell passaging even in the
absence of ROCKi.
Results
IaI and its HC2 domain induce hPS cell attachment. To study
whether IaI could support stem cell attachment, K2C hiPS cells
were seeded onto standard TC-treated plastic in E8 medium
supplemented with 50mgml 1 IaI. The purity of the isolated IaI
protein solution was thoroughly validated through silver staining
and mass spectrometry analysis (Supplementary Fig. 1). Cell
attachment was assessed 4 h after seeding using crystal violet
staining, and VN-XF coated plates (E8:VN) were used as positive
control. Figure 1a shows how IaI supplementation induces
similar cell attachment levels as VN-XF coating. The separate Bk
and HC1 IaI domains were unable to support attachment when
added in solution to the medium (Supplementary Fig. 2; Fig. 1a).
However, when HC2 (but not HC1) was pre-coated onto
standard TC-treated plastic, similar attachment levels, as with IaI
supplementation, were achieved 4 h after seeding (Fig. 1a).
Cells seeded in IaI or on HC2-coated plates exhibited similar
colony morphology and cell–cell contacts (deﬁned by E-cadherin
arrangement) as cells seeded on VN-XF (Fig. 1b; Supplementary
Fig. 3). To further investigate the role of the different IaI domains
in the hPS cell attachment we added antibodies against each
of the three IaI domains at the seeding step. Even though the use
of the separate IaI domains showed HC2 to be responsible for
the hPS cell attachment, all three antibodies inhibited IaI-induced
attachment regardless of which domain was being targeted,
suggesting that antibody binding hinders IaI-mediated
attachment when used in solution (Fig. 1c).
Serum albumin inhibits IaI-mediated attachment. When an
alternative stem cell culture medium, mTeSR1 (which contains a
high concentration of bovine serum albumin (BSA, 1% w/w) and
b-Mercaptoethanol, was used as basal medium for IaI,
signiﬁcantly lower cell attachment was achieved as compared
with using E8 medium (determined by paired t-test). We
therefore hypothesized that BSA may bind and sequester IaI,
reducing its effective concentration in the medium. To test this,
IaI-mediated attachment of the hES cell line HUES1 and the
hiPS cell line K2C was measured in E8 medium, E8 medium
supplemented with 5% w/v BSA or mTeSR1 medium. Addition of
BSA to the E8 medium signiﬁcantly reduced IaI-mediated
attachment (determined by paired t-test) to similar levels as those
observed when using mTeSR1 (Fig. 1d). Albumin is commonly
used to block non-speciﬁc binding to plastic or other surfaces
because of its rapid and wide-ranging binding capacity.
To conﬁrm that the inhibition of IaI-mediated attachment
observed in the presence of albumin was not due to a competition
for surface coating, we pre-coated the surface with 50mgml 1
IaI for 1 h at room temperature (RT) before seeding hPS
cells in either E8 medium or mTeSR1 medium. Again, the
attachment was lower in mTeSR1 as compared with the E8
medium, further conﬁrming that albumin can indeed reduce
the ability of IaI to promote cell attachment, possibly by binding
to it directly and thereby blocking its effect (Supplementary
Fig. 2).
Integrins are involved in IaI-mediated attachment. The HCs
contain a von Willebrand type A (vWA) domain, which has
been reported to bind proteins such as VN via RGD (arginine-
glycine-aspartate) motifs25. To assess if the observed effect of
IaI supplementation was mediated by integrin engagement of
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RGD-motifs, a panel of RGD-blocking peptides were tested for
their ability to inhibit IaI-mediated attachment (Fig. 1e). The
linear RGD peptide H1830 did not have an effect, but the cyclic
RGD-based, avb3- and avb5-blocking peptides (c(RGDfV),
H-2574 (ref. 26)) and (c(RGDfC), H-7226 (ref. 27))
signiﬁcantly reduced attachment as compared with their
controls c(RADfV) and c(RADfC) (H-4088 and H-7232,
respectively) (determined by paired t-test). These peptides block
attachment to VN and LN, which have been shown to support
hPS cell attachment and survival4,5,7. The GRGDsP (H-3164)-
blocking peptide, which reduces attachment to ﬁbronectin but
does not interfere with VN-mediated binding, did not reduce
IaI-induced attachment (all peptides were from Bachem and are
described in Supplementary Table 1).
To conﬁrm the results obtained with the RGD-blocking
peptides, we used blocking antibodies against VN and LN-
binding integrins together with the E8:IaI method. The antibodies
were added at the seeding step and cell survival and growth was
assessed after 4 days. Blocking the av and b1 integrin domains
and the avb5 integrin drastically affected attachment, while the
avb3-blocking antibody reduced the attachment to a lesser extent
(Fig. 1c). The b1 integrin domain has been shown to be the main
integrin domain responsible for hPS cell binding to LN3,4,
while av has been described as VN binding in hPS cells when
present in avb1, avb3 and avb5 complexes28. Together, these
results point towards the involvement of multiple integrin
subunits in IaI-mediated attachment, in contrast to the limited
number of subunits involved in binding to simple ECM-derived
fragment coatings3.
HA is involved in IaI-mediated attachment. HA is a non-
sulphated GAG found in many matrices throughout the body
where it affects multiple functions including cell migration and
proliferation. HA hydrogels have also proven useful for hPS cell
culture and delivery29. The HCs of IaI are the only proteins yet
described to bind covalently to HA, and we therefore investigated if
HA was involved in the IaI-mediated attachment of hPS cells.
CD44 is a common HA-receptor and has been linked to cancer cell
attachment and transformation following HA binding. However,
we observed no inhibition of IaI-induced attachment in the
presence of a CD44-blocking antibody (Fig. 1c). The involvement
of GAGs in IaI-mediated attachment was further studied using a
chemical inhibitor of GAG synthesis, 4-methylumbelliferone
(4-MU)30,31. The hES cell line HUES1 was treated with 0.6mM
of 4-MU for 24 h before passaging and seeded onto VN-coated
plates or E8:IaI, with 0.6mM 4-MU supplementation. As shown in
Supplementary Fig. 4, 4-MU treatment signiﬁcantly reduced
IaI-mediated attachment to B75% of the control samples, and
this reduction was not observed for VN-mediated attachment
(determined by one-way ANOVA analysis and Dunnett’s post-test
against negative control E8:VN). Whilst it is noted that a reduction
in GAG synthesis may impact multiple aspects of cell behaviour,
attachment of 4-MU-treated cells could be fully recovered by
adding exogenous high molecular weight HA (HMW-HA,
2,000–2,400KDa) therefore suggesting that HA may be involved
in E8:IaI-mediated attachment, however via a non-CD44-related
mechanism (determined by one-way ANOVA analysis and
Dunnett’s post-test against negative control E8:VN, and paired
t-test against 4-MU-treated E8:IaI sample).
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Figure 1 | IaI and IaI domain HC2 can support attachment and survival of hPS cells. (a) Quantiﬁcation of cell attachment by crystal violet staining 4 h
after seeding of hiPS cell line K2C added to plates with 10mgml 1 VN-XF coating, 50mgml 1 IaI medium supplementation, 50mgml 1 HC1 coating or
50mgml 1 HC2 coating. (b) Immunoﬂuorescence of hES cell line HUES1 on VN-XF coating or IaI supplement showing E-cadherin (left panel) and Oct4
(right panel), scale bar shows 100 mm. (c) Cell survival and growth assayed with crystal violet staining after 4 days of culture of HUES1 and K2C in E8
medium with IaI and different blocking antibodies, (d) E8 medium with or without 50mgml 1 IaI (E8:IaI), 5% BSA (w/v) in E8: IaI, and mTeSR1 medium
with or without IaI; (e) E8 medium supplemented with IaI and IaI together with different integrin-blocking peptides. All cell-number quantiﬁcation
experiments were performed in triplicate over three separate experiments. Bars show mean±s.e.m. and statistical analysis over the three independent
experiments. Statistical analysis indicates signiﬁcant differences with *Po0.05, **Po0.001 and ***Po0.001 determined by One-way ANOVA and
Dunnett’s post-test. Speciﬁc comparisons were done with paired t-test and are shown by a connective line between the two sets of samples.
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Live monitoring of the hES cell line HUES1 shows how IaI
induces cell attachment and spreading over a similar timeframe
and in a similar manner as the VN-XF coating (Supplementary
Movie 1). Thus, IaI appears to exert a direct effect on cell
attachment, similar to VN-XF coating, with attachment and
spreading as concurrent events. The above data therefore point
towards a complex attachment process, likely to involve several
membrane receptors and extracellular ligands.
IaI efﬁciently supports single-cell passaging of hPS cells. To
further evaluate IaI-induced hPS cell attachment and growth;
HUES1 and K2C hPS cells were dissociated into small aggregates
using a gentle enzyme-free reagent (Gentle Cell Dissociation
Reagent (GCDR, Stem Cell Technologies)), or into single cells
using TrypLE (a recombinant cell-dissociation enzyme,
ThermoFisher) with ROCKi supplementation. The cells were
then seeded using E8:VN or E8 with different IaI concentrations
ranging from 0 to 500mgml 1. On day 4, cell density was
assessed using crystal violet staining. As shown in Fig. 2 and
Supplementary Fig. 5, 40–100 mgml 1 of IaI was able to support
attachment, characteristic colony morphology and positive
alkaline phosphatase staining; 50 mgml 1 IaI was therefore
selected for all subsequent experiments (and is denoted as E8:IaI).
It was also conﬁrmed that IaI addition is only required during
seeding and the initial attachment process, and is not required in
subsequent medium exchanges.
When sub-culturing in small aggregates, 50 mgml 1 of IaI
supplementation at the seeding step supported similar viability as
VN-XF coating. However, when performing single-cell splitting,
almost no cells had survived after 4 days on VN-XF coating
even with the addition of 10 mM ROCKi to the culture during the
ﬁrst 24 h after seeding. In contrast, under these conditions,
IaI supplementation supported very high cell survival, with cells
reaching a monolayer after 4 days. Further analysis showed that
IaI was also able to support survival and colony formation of
dissociated single cells in the absence of ROCKi, although
the survival rate was lower than with ROCKi (Fig. 3a,b).
Live monitoring of hES cells (HUES1) cultured in the absence
of ROCKi showed that although the cells initially attach and
spread as single cells on VN-XF coating, they eventually lift off
the plate and die, while HUES1 cells seeded in the presence of IaI
exhibit decreased motility after seeding but stronger cell-to-cell
contact formation, and grow as adherent colonies until they are
ready to be passaged (Supplementary Movie 2).
As presented above, in the absence of ROCKi pre-treatment,
no hPS cell survival was observed on VN-XF coating. A 1-h
pre-treatment with ROCKi is usually recommended for single-cell
splitting of hPS cells to increase cell survival12. However, in our
hands, 1-h pre-treatment resulted in inconclusive results when
using the E8:VN method, even at high seeding densities. To
prevent this, the ROCKi pre-treatment step was increased to 5 h.
This longer pre-treatment improved the survival in E8:VN,
but not to the level seen with E8:IaI. Thus, as shown in
Supplementary Fig. 6a, there was a consistent higher cell density
after 4 days in E8:IaI cultures when compared with VN-XF
coating, from very low cell-seeding densities (25 cells per cm2) up
to typical seeding densities (103 cells per cm2).
IaI protects from residual protease remaining after passage. IaI
has been reported to act as protease inhibitor through its bikunin
domain32. E8 is a low-protein medium and therefore, small
traces of protease remaining in the culture medium after splitting
could result in cell damage and subsequent death due to the
lack of protease inhibitors. TrypLE is a recombinant protease
that has been reported to be more gentle on the cell surface, and is
therefore recommended for stem cell culture33. To investigate if
the reduced cell survival observed using VN coating together
with single-cell splitting is caused by remaining traces of TrypLE
in the medium, we used a 5-h ROCKi pre-treatment followed
by TrypLE passaging with a dilution and centrifugation step to
remove all TrypLE remains. The cells were then seeded with and
without the addition of 1% (V/V) of TrypLE. Supplementary
Fig. 6b shows that while E8:IaI could support B100% survival
of hES cell line HUES1 in 1% TrypLE, VN coating was unable
to support cell survival in 1% TrypLE. These data suggest that
IaI is able to partially protect against residual TrypLE in the
medium after passaging.
VN in solution does not support single-cell seeding. According
to the manufacturer’s recommendations, the VN peptide should
be used as a coating agent in combination with E8 medium.
To determine whether VN could be added in solution, similar to
IaI, cells were pre-treated with ROCKi for 5 h and single cells
were then seeded on either VN-coated plates or on uncoated
plates in E8 medium supplemented with 10mgml 1 VN or
50 mgml 1 IaI. As shown in Supplementary Fig. 6c, VN added
in solution could not support attachment and survival to the
same extent as IaI added in solution or coated VN, demon-
strating that IaI-induced cell attachment is not only a result
of rapid coating of the tissue culture plastic and that VN is only
able to support attachment when used as a coating agent
(Supplementary Fig. 6c).
IaI increases clonal survival of hPS cells. Live imaging of NCL1
hES cells seeded in E8:IaI with ROCKi after single-cell splitting
revealed a colony forming from one single cell, suggesting that
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Figure 2 | IaI attachment is concentration dependent. Dose–response curve of hPS cell lines HUES1 and K2C seeded as (a) small clumps (GCDR) or (b)
single cells with ROCKi (TrypLEþ 10mM ROCKi after seeding, no ROCKi pre-treatment) using increasing concentrations of IaI in E8 medium, compared
with VN-XF coating. All cell-number quantiﬁcation experiments were performed in triplicate over three separate experiments. Bars show mean±s.e.m.
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IaI can support clonal growth (Supplementary Movie 3).
We therefore assessed the cloning success rate for six different
hPS cell lines (K2C, HUES1, H207, H181, NCL1 and K8F)
cultured in E8:IaI or E8:VN. High cloning rates of up to 18%
were achieved with E8:IaI, and the cloning efﬁciency was
consistently higher using the E8:IaI protocol as compared with
E8:VN protocol in all ﬁve hPS cell lines tested, despite using a 5 h
pre-treatment with ROCKi (Table 1).
Easy adaptation of hPS cell lines to E8:IaI. To ensure that the
E8:IaI protocol can support robust propagation and pluripotency
of different hPS cells, six hES cell lines (HUES1, H181, H207,
OXF2, NCL1, huES3-Hb9::GFP) and two hiPS cell lines (K2C and
K8F), originally derived in four different laboratories, were
adapted to E8:IaI. All hPS cell lines exhibited normal morphology
in E8:IaI medium (Supplementary Fig. 3a). The E8:IaI protocol
showed better adaptation efﬁciency of the hES cell line OXF2
from feeder-cell culture as compared with E8:VN. Through a
simple step-wise adaptation protocol, combining E8:IaI and
single-cell passaging using TrypLE dissociation and ROCKi
(Fig. 4a), we achieved 100% adaptation efﬁciency of ﬁve different
feeder-dependent hPS cell lines (OXF2, NCL1, huES3::Hb9rGFP,
K2C and K8F), with approximately four-fold better yield as
compared with the E8:VN protocol for OXF2 hES cells (Fig. 4b).
Healthy colony formation was achieved at passage 1 and
negligible differentiation was observed from passage 2 (Fig. 4c).
Successful adaptation of NCL1 was particularly noteworthy since
this line had, in our hands, proved incompatible with feeder-free
culture. These data suggest enhanced adaptation efﬁciency of
feeder-dependent hPS cell lines to E8:IaI. Assessment after 5–10
passages proved expected stem cell marker expression (Fig. 4c).
IaI supports long-term propagation of hPS cells. Three hES cell
lines (HUES1, H207 and H181) and one hiPS cell line (K2C) were
then cultured for 15 or more passages in E8:IaI. The E8:VN
protocol was used as positive control and, for adequate
comparison, cells were split in small clumps for both protocols.
All cell lines grew as tight colonies with negligible signs of
differentiation regardless of culture condition. E8:IaI also
supported freeze-thaw cycles with survival rates after recovery
similar to E8:VN. Proliferation rate was assessed for up to 40 days
(10 passages) and showed similar growth rates independent of
culture protocol and cell line (Fig. 5a). Immunoﬂuorescence
staining highlighted strong and speciﬁc expression of stem
cell markers in all cell lines after 15 or more passages in both
protocols (Fig. 6a; Supplementary Fig. 7).
The Human Stem Cell Pluripotency TaqMan array
(ThermoFisher) was performed to characterize expression
proﬁles of the four hPS cell lines after long-term propagation
focusing on marker genes for pluripotency, stemness and
differentiation34. No signiﬁcant differences in transcription
proﬁles were found between culture conditions (as determined
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Table 1 | IaI increases cloning efﬁciency of hPS cells.
hPS line Culture Method Number of wells Number wells with 1 colony Cloning efﬁciency (%)
HUES1 E8:VN 298 7 2.3
HUES1 E8:IaI 451 50 11.1
K2C E8:VN 100 0 0
K2C E8:IaI 200 10 5
H207 E8:VN 100 1 1
H207 E8:IaI 93 7 7.5
H181 E8:VN 200 2 1
H181 E8:IaI 200 14 7
K8F E8:VN 300 29 9.7
K8F E8:IaI 284 32 11.3
NCL1 E8:IaI 275 50 18.2
Cloning efﬁciency of individualized HUES1, K2C, H207, H181, K8F and NCL1 hPS cells in 96-well plates using E8:IaI (E8 medium with 50mgml 1 IaI supplementation) or E8:VN (E8 medium on
vitronectin-coated surface) with 5-h pre-treatment and supplementation of 10mM ROCKi for the ﬁrst 48 h. Assessment of colonies was done 14 days after seeding through MTT assay.
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by multiple comparisons using two-way ANOVA and Sidak’s
Multiple test), indicating that IaI does not induce differentiation
or reduce expression of stem cell related markers (Fig. 5b,c;
Supplementary Fig. 8; Supplementary Data 1). In fact, when
relative expression values for stem cell markers were assessed
closely, it was found that hPS cells grown in E8:IaI showed a
more compact expression proﬁle than hPS cells grown in E8:VN
(Fig. 5b,c; Supplementary Fig. 8). The cells were then subjected
to spontaneous differentiation by embryoid body formation
and subsequent plating onto Matrigel with serum-containing
medium. After 4 weeks, all hPS cell lines, independent of previous
culture condition, showed successful differentiation into the three
germ layers as assessed by immunoﬂuorescence staining for
speciﬁc markers (Fig. 6a; Supplementary Fig. 9a,b). TaqMan
array was then performed on the differentiated hPS cell samples
and again, no differences in transcriptional proﬁles were found
between the two culture methods (Fig. 5b; Supplementary
Data 1). Moreover, as shown in Supplementary Movie 4, K2C
hiPS cells successfully produced beating cardiomyocytes after 40
passages in E8:IaI.
IaI supports directed endoderm differentiation. Endoderm has
been the most difﬁcult germ layer to generate in vitro35. To
investigate if IaI could also support directed differentiation
protocols for hPS cells, we combined the STEMDiff Deﬁnitive
Endoderm Kit (TeSR-E8 optimized, StemCell Technologies) with
IaI. Brieﬂy, four hPS cell lines grown in E8:IaI for 10 or more
passages were pre-conditioned to endoderm before being split as
single cells and seeded using IaI. All four hPS cell lines attached
normally and survived throughout the ﬁve-day differentiation
protocol. The results showed that cells cultured in E8:IaI can
be readily induced to differentiate into endoderm, generating a
monolayer of endoderm precursor cells, positive for the key early
endoderm markers Sox7, Sox17 and HNF3b (ref. 36; Fig. 6b;
Supplementary Fig. 10).
IaI does not increase genetic abnormalities. To ensure that IaI
does not increase the level of mutations or chromosomal
abnormalities after long-term culture when compared with
current methods, all hPS cell lines were subjected to G-banding
and the Human OmniExpressExome array (Illumina, SNP&SEQ
Technology Platform, Uppsala University). Single-nucleotide
polymorphism (SNP) array data were analysed both by total
number of copy-number (CN) calls, and number of shared CN
calls between early and later passage (Supplementary Tables 3
and 4; Supplementary Fig. 11). G-banding analysis showed few
but equal amounts of abnormalities in both culture methods
(Supplementary Table 2; Supplementary Fig. 12). Further analysis
done by using SNP-array data indicates that the CN proﬁles
changed during culturing regardless of protocol used and cell line
examined and that the two examined protocols perform equally
well in retaining genetic proﬁles (Supplementary Table 3).
A stricter CN analysis was also performed by comparing the
number of shared CN calls between early and late passages in
each of the four cell lines under the two protocols and for all 123
CN calls (Supplementary Table 4). Overall, we found no
difference in the number of genetic alterations detected
(Wilcoxon rank-sum-test; W¼ 10.5, P¼ 0.8082). No increase in
genetic abnormalities was observed in E8:IaI as compared with
E8:VN and the starting passages, suggesting that IaI does not
increase the risk of genetic aberrations or selection for
advantageous mutations in long-term culture. Even though the
presence of abnormalities in all conditions may seem alarming,
the hPS cell lines used in this study were obtained at high
passages, and it has been reported that hPS cell lines can
develop abnormalities after long-term culture in vitro37. Indeed, a
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previous large-scale analysis of 125 independent hPS cell lines
from 38 different laboratories reported that small variations
similar to the ones present in this study could be found in all
samples, and documented that these are consistent with previous
structural variants studies made on human populations, therefore
dependent on their source genome and not from their in vitro
culture38.
Discussion
The last few years have seen a marked reﬁnement of hPS cell
culture methods, enabling the use of better deﬁned culture
conditions as well as simpliﬁed handling protocols, essential for
the widespread use of hPS cells. The potential of hPS cells as
renewable cell sources for drug toxicity screening, human cell
therapy and regenerative medicine has rendered traditional cell
culture methods, based on ill-deﬁned components, unsuitable39.
For this purpose, several deﬁned surfaces have been developed to
improve hPS cell derivation and expansion40,41. However, none
of the currently available methods fulﬁl all requirements for
simple, robust, cost-efﬁcient and safe production of hPS cells. The
combination of E8 medium with VN-XF5 coating is both deﬁned
and animal-component free, and has been proven to successfully
support long-term culture of hPS cells when passaged as small
clumps. However, this method requires a surface pre-coating step
and, as shown in the present work, is inefﬁcient when hPS cells
are passaged as single cells.
In this paper we present IaI as a protein able to induce
attachment of hPS cells onto plastic without the need for a pre-
coating step. This is the ﬁrst time that IaI has been reported to
induce attachment in in vitro culture, particularly remarkable
considering the extensive and numerous efforts to identify
substrates for hPS cell culture. During this study we discovered
that high concentrations of albumin in culture medium reduce
IaI-induced attachment to B50%. These results suggest that
albumin binds IaI and reduces its ability to induce cell
attachment, both when present as a soluble factor and a
pre-coated agent. This is possibly the reason why this is the
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ﬁrst study linking IaI to cell attachment, as the majority of
traditional cell culture media contain high concentrations of
albumin.
IaI is a relatively large protein that consists of three distinct
globular domains: Bk, HC1 and HC2. We found that antibodies
targeted against any of the IaI domains could block IaI-induced
attachment of hPS cells when IaI was used in solution. However,
the only domain that could support hPS cell growth on its
own was HC2, and only when HC2 was used as a coating agent.
These results concur with our previous report showing
that the HC2 domain of IaI, but not the HC1 domain, can
activate pluripotency-related transcription in mES cells24. It has
also been reported that transfer of the HC domains to HA
requires the HC2 domain to be present, as part of the IaI
molecule or as a separate domain (for example, HC2-Bk)20,23,
conﬁrming the distinct biological activity of the HCs. While
HC1 and HC2 share functional domains (a vault protein
inter-a-trypsin (VIT) domain and a vWA domain), outside of
these regions there is considerable heterogeneity, and overall,
human HC1 and HC2 only share 39% amino acid identity.
While little is known about the function of the VIT domain,
the vWA domain has been reported to bind many proteins via
RGD domains, including VN25. Thus, to assess if the IaI-induced
attachment was integrin mediated, we used RGD-blocking
peptides as well as integrin-blocking antibodies and found
that multiple integrin subunits were likely to be involved in
the process, pointing to a more complex interaction than the
traditional integrin-binding protein attachment of VN- and
LN-based coatings. Since the HCs of IaI are the only proteins
reported to bind covalently to HA, we also investigated the
potential role for HA in IaI-mediated attachment. Blocking the
HA receptor CD44 did not have any effect on IaI-induced
attachment. However, reducing GAG synthesis using an inhibitor
decreased IaI-mediated attachment, indicating that HA may
play a role IaI-mediated attachment. Overall, our results point to
IaI-induced attachment being the result of a synergistic
combination of several extracellular molecules and surface
receptors. Indeed, IaI has been reported to interact with several
extracellular molecules, including HA20, integrin-binding
proteins such as VN25, and the complement system42. In vivo,
many different processes have been linked to IaI, including the
cumulus formation of the oocyte43, ﬁbrosis and angiogenesis22,
tissue repair25, amniotic membrane formation44,45, arthritis46 and
others. IaI is proving to be a very versatile protein with a wide
variety of functions, which most likely depend on the different
partners it can interact with in each situation. Clearly, further
study will be needed to completely unravel the mechanism
underpinning IaI-mediated attachment.
In this study we present the ﬁrst hPS cell culture protocol that
overcomes the need for specialized surface coating or functiona-
lization, while still being deﬁned and animal-component free.
This method is highly time efﬁcient, as coating is a time-
consuming step in hPS cell culture methods. We demonstrate that
E8:IaI improves single-cell passaging and cloning efﬁciency,
without the need for a lengthy ROCKi pre-treatment, and can
protect from residual protease, thus making automated handling
simpler and enabling cell-number control and high-throughput
experimental design. Long-term propagation and characterization
of four different hPS cell lines and successful adaptation of a total
of eight different hPS cells lines prove that this culture method is
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Figure 6 | IaI maintains pluripotency and differentiation capacity in long-term culture. Immunoﬂuorescence staining of H207 hES cell line for (a) stem
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reliable and robust. Moreover, we have shown that IaI can
support a directed differentiation protocol. E8:IaI can also
support freeze-thaw cycles in the same manner as commercially
available methods. The IaI used in this study was derived from a
side fraction of human plasma used for commercial factor
IX production, with purity above 95%, as described
previously14,21,24. IaI has a long shelf-life and can potentially be
puriﬁed and prepared in large quantities from human plasma at
GMP grade and at a reasonable cost. Future development will also
investigate on the possibility of using recombinant IaI, or parts
thereof. In conclusion, this simple method offers a reliable and
cost-efﬁcient solution to the current need for deﬁned hPS cell
culture conditions and has great potential to transform research,
pharmacological and clinical application of hPS cells and their
derivatives.
Methods
Materials and cell lines. Cells: hES cell lines H181, H207 (kindly provided by
Dr Hovatta from Karolinska Institutet, Stockhom), HUES1 and HUES3-Hb9::GFP
(kindly provided Dr Melton and Dr, Eggan from Harvard Stem Cell Institute and
Dr. Koslova from Uppsala University), OXF2 and NCL1 (UK Stem Cell Bank), and
hiPS cell lines K2C and K8F (generated by Dr Schuster, Uppsala University).
Primary antibodies: mouse anti-Oct4 (POUF5F1) cl. 7F9.2 (Millipore), rabbit
anti-Nanog (ab109250, Abcam), mouse anti-Sox2 (ab171380, Abcam), mouse
anti-SSEA-4 (MAB4304, Millipore), mouse anti-Tra-1-81 (MAB4381, Millipore),
mouse anti-Tra-1-60 (MAB4360, Millipore), mouse anti-a-Fetoprotein (AFP)
receptor (MAB4086, Millipore), rabbit anti-PDGFb receptor (sc-432, Santa Cruz
Biotechnology), mouse anti-Neuron speciﬁc b-III-tubulin (MAB1195, R&D),
rabbit anti-E-cadherin (#3195, Cell Signaling Technology), mouse anti-a-Smooth
Muscle Actin (aSMA) (CBL171, Millipore), rabbit anti-nestin (ab105389, Abcam),
mouse anti-HNF3b (sc-101060, Santa Cruz Biotechnology), mouse anti-Sox17
(SAB3300046, Sigma), rabbit anti-Sox7 (HPA009065, Sigma). Blocking antibodies
used were: mAB13 (ref. 47) anti-b1 (kindly provided by Dr. Kenneth Yamada,
NIDCR, USA), anti-av L230 (ab94704, Abcam), anti-avb3 (MAB1976, Millipore),
anti-avb5 (ab24694, Abcam), anti-ITIH1 K-16 (sc-33944, Santa Cruz
Biotechnology), anti-ITIH2 N-17 (sc-21974, Santa Cruz Biotechnology), anti-Bk
P-20 (sc-21597, Santa Cruz Biotechnology), rat anti-CD44 KM114 (kindly
provided by Dr. Paraskevi Heldin, Uppsala University). Secondary antibodies:
Alexa Fluor 488 goat anti-mouse (ThermoFisher), Alexa Fluor 555 goat anti-rabbit
(ThermoFisher). Other reagents: Hoechst 33342 (ThermoFisher), Matrigelt
Matrix hES-qualiﬁed (Corning), RGD-based blocking peptides (all from Bachem,
described in Supplementary Table 1), Y-27632 (ROCK inhibitor, ROCKi, StemCell
Technologies), 25% hES-qualiﬁed BSA (Invitrogen), high molecular weight HA
2,000–2,400 kDa (HMW-HA, Cat No. 73641, Sigma-Aldrich), and 4-Methy-
lumbelliferone (4-MU, M1381, Sigma).
Cell culture. The hPS cell starting cultures were on Matrigel coating (Corning) in
mTeSR1 medium (StemCell Technologies)11 or on feeder cells (gamma-irradiated
MEFs or CRL-2429 HFFs) in 20% KOSR and 8 ngml 1 bFGF supplemented
KO-DMEM48. Continuous culture on VN-XF and E8 medium was performed
following manufacturer’s instructions. Brieﬂy, vitronectin coating was performed
by diluting VN-XF (StemCell Technologies #07180) in Dilution Buffer (StemCell
Technologies #07183) to a ﬁnal concentration of 10 mgml 1, then immediately
using the solution to coat non-tissue culture-treated cultureware, gently mixing the
solution by rocking. The solution was allowed to coat for at least 1 h at RT or
overnight (ON) at 4 C. The coated well was washed once with the dilution buffer
before use. The hPS cells were harversted using the Gentle Cell Dissociation
Reagent (GCDR, StemCell Technologies #07174), the E8 medium was removed
and the appropriate volume of GCDR was added and incubated for 5–8min at RT.
Then the solution was removed and the appropriate volume of E8 medium added,
the colonies were scrapped using a cell lifter (Corning, CLS3008) and broken down
by pipetting up and down 4-5 times. After that the cells were seeded using a
dilution according to the initial density, typically ranging from 1:4 to 1:10.
Culture of hPS cells in E8:IaI. For the continuous culture of hPS cells in
E8:IaI the cells were grown until appropriate size before splitting using GCDR
(StemCell Technologies #07174). Brieﬂy, the medium was removed; the appro-
priate volume of GCDR was added to the wells and incubated at RT for 5–8min.
The GCDR solution was removed and the appropriate volume of E8 medium was
added, the colonies were then harvested using a cell lifter (Corning, 900020) and
broken down by pipetting up and down 4–5 times. The wells were split 1:4 to 1:10
(depending on starting cell density), fresh E8 medium together with the hPS cells
was added into a new, uncoated, tissue culture-treated plastic (Corning). Finally,
50mgml 1 IaI was added into the well and mixed by gentle rocking. The culture
medium was changed daily using standard E8 medium. IaI supplementation was
not necessary after the initial seeding step.
Adaptation of feeder-dependent PS cells to E8:IaI. The hPS cells cultured on
feeder cells were adapted to E8 medium using a 4-day step-wise adaptation from
the original medium to the E8 medium. On day 4, the cells were harvested using
TrypLE and then seeded in E8 medium supplemented with 10 mM Y-27632 onto
tissue culture-treated plastic with 50 mgml 1 IaI supplementation or onto VN-XF
coated surfaces, cell density used was approximately 5 103 cell per cm2. The
medium was then changed daily until day 4, when cells were passaged or assessed
for total cell number. After the ﬁrst passage, continuous culture passaging was done
using GCDR.
Growth-rate assessment. The hPS cell lines were split for routine culture using a
GCDR and collected using a cell lifter. For the growth-rate assessment, duplicates
were kept for every condition. One well was passaged with GCDR for continued
culture, while the other was passaged with TrypLE for cell-number measurement
with a TCP counter (Bio-Rad).
Cryopreservation of hPS cells. The cells were harvested using GCDR and a cell
lifter. The freezing medium used was mFreezer or FreSR-S (StemCell Technologies)
and the ﬁnal cell concentration ranged from 4-10 106 cells per ml. Cell solution
(1ml) was used per cryovial, the cells were then transferred to a  80 C freezer for
a slow-cooling using an isopropanol freezing container. After 24 h, the cryovials
were transferred to permanent storage in vapour phase liquid nitrogen.
Differentiation. Embryoid body (EB) formation was performed using the
aggrewell system (StemCell Technologies), harvesting the cells using TrypLE with
1-h ROCKi pre-treatment and seeding an average of 2,000 cells per EB and with
ROCKi addition. The EBs were then kept in GMEM 20% FBS and suspension for 2
weeks and then plated onto Matrigel (Corning) or Synthemax (vitronectin,
Corning) for 2 more weeks. Beating cardiomyocytes areas were ﬁlmed after 3–4
weeks of growth using a light-phase microscope coupled to a NikonE990 camera.
Puriﬁcation of human IaI. A side fraction from the commercial manufacturing of
factor IX (Pharmacia-Upjohn, Stockholm, Sweden) was fractionated using gel
ﬁltration chromatography on a HiPrep 26/60 Sephacryl S-400 HR column using the
A¨KTA automated chromatography system (both from GE Healthcare). This process
generates more than 95% pure IaI. For the release of the heavy chains, a solution of
1mgml 1 IaI in PBS was subjected to 0.05 M NaOH treatment for 15min at RT
and then dialyzed against 20mM sodium phosphate pH 7.6 and subsequently
applied to an anion-exchange chromatography for separation using the A¨KTA
system (MonoQ 5/50 GL; GE Healthcare)49. Fractions were analysed in 8%
acrylamide SDS–PAGE gels and Coomassie Brilliant Blue staining. Unless speciﬁed
otherwise, protein concentrations were determined by UV measurements and using
the absorbance coefﬁcients for the protein moieties of IaI, HC1 and HC2 obtained
from Bloom et al.14 The protein solutions were concentrated and stored at  20 C.
Crystal violet attachment assay. The hPS cells were collected with either with
GCDR or TrypLE. Approximately 5 103 cell per cm2 were seeded, unless speciﬁed
otherwise. For single-cell splitting, 4–5 h of 10mM ROCKi pre-treatment was used
(unless stated otherwise) and the dissociation reagent was TrypLE (ThermoFisher).
For single-cell splitting 10mM ROCKi was also added for the ﬁrst 24 h after seeding,
unless speciﬁed otherwise12. After the speciﬁed time for attachment and/or growth,
total cell number was assessed50. Brieﬂy, the plates were washed twice with PBS to
remove non-attached cells and ﬁxed using ice-cold methanol for 10min, and
subsequently stained with 0.4% w/v crystal violet in methanol for 5min. The crystal
violet was then thoroughly washed away using distilled water, and the plates were
dried before adding 175ml of 0.1% SDS solution per 24-well plate well. After 1–2 h on
a tilting table at RT, quantiﬁcation was performed measuring optical density at
570 nm with Multiscan PLUS (Labsystems). All cell-number quantiﬁcation
experiments were performed in triplicates, with three separate independent
experiments performed, unless speciﬁed otherwise. The samples were also
periodically randomized so as to ensure no position-related variations.
Attachment blocking. The hPS cells were harvested as small clumps using GCDR
and seeded at 5 103 cells per cm2 in E8 supplemented with 50mgml 1 IaI
(E8:IaI) with the addition of each antibody at 5 mgml 1 for the integrin-blocking
antibodies, and 20 mgml 1 for the IaI-binding antibodies for the ﬁrst 24 h. The
RGD-blocking peptides were also added at the seeding step at a concentration of
25 mM (9–15 mgml 1). The cells were cultured for 4 days before cell survival and
growth was assessed using crystal violet staining.
GAG synthesis inhibition. The inhibitor 4-Methylumbelliferone (4-MU) was used
to inhibit GAG synthesis in the hPS cells to assess its effect of on the IaI-mediated
attachment. Brieﬂy, hPS cells were treated for 24 h in E8 medium supplemented
with 0.6mM 4-MU or with 6ml MeOH as a negative control. This concentration
has been reported to decrease HA synthesis without inducing apoptosis in
cancer cell lines31. After treatment the cells were harvested as small clumps using
GCDR and seeded onto VN coating or with IaI, with the addition of MeOH or
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4-MU for the ﬁrst 24 h after seeding. Moreover, in the 4-MU-treated samples
100mgml 1 HMW-HA was also added to assess the effect of exogenous HA.
Directed endoderm differentiation. Directed endoderm differentiation was per-
formed using the STEMDiff Deﬁnitive Endoderm Kit (TeSR-E8 optimized, StemCell
Technologies), according to the manufacturer’s instructions. Four hPS cell lines
cultured on E8:IaI conditions were grown for 4 days. At day four, the medium was
changed to Pre-differentiated supplemented E8 medium and used for daily
exchanges for 48 h. The cells were then washed with PBS and split using GCDR and
thorough pipetting to achieve a single-cell suspension. The single suspension
was centrifuged and resuspended in E8 medium supplemented with IaI and
pre-differentiation reagent, and seeded at 2 105 cells per cm2. After 24 h, the
medium was changed to StemDiff Deﬁnitive Endoderm Basal medium supple-
mented with reagents A and B. On day 2, the medium was changed into StemDiff
Deﬁnitive Endoderm Basal medium supplemented with reagent B, and this medium
was used to exchange daily until day 5. The cells were then ﬁxed and used for
immunocytochemistry analysis.
Immunocytochemistry. Cells were ﬁxed with cold 4% paraformaldehyde (Sigma)
for 15min and then blocked with 0.5% BSA and 0.3% Triton X-100 in PBS (all from
Sigma). The primary antibodies anti-Oct4 (1:300), anti-Nanog (1:100), anti-Sox2
(1:100), anti-SSEA-4 (1:200), anti-Tra-1-60 (1:100) and anti-Tra-1-81 (1:100),
anti-bIII-Tubulin (1:100), anti-Nestin (1:200), anti-aSMA (1:200), anti-AFP (1:50),
anti-PDGFb receptor (1:50), anti-E-cadherin (1:100), anti-Sox7 (1:50), anti-Sox17
(1:50), anti-HNF3b (1:100), were added to the cells and incubated in a humid
chamber at 4 C overnight, rinsed with PBS, and subsequently incubated with Alexa
Fluor 555 anti-rabbit (1:500) and/or Alexa Fluor 488 anti-mouse (1:500) for 60min
at room temperature. After rinsing with PBS and co-staining with Hoechst 33342,
coverslips were mounted using ﬂuoromount (Sigma), and analysed with inverted
confocal ﬂuorescent microscopy (LSM700, Zeiss). All images were uniformly pro-
cessed using Adobe Photoshop CS6 (Version 13.0.6 x64).
Human stem cell pluripotency taqman array. Total RNA was extracted using an
RNeasy Mini kit (Qiagen) following manufacturer’s instructions. An RNA
nano6000 chip and a Bioanalyser2100 (Agilent) were used to assay RNA quality,
and only samples with an RNA integrity number (RIN) Z8 were selected for the
array. cDNA was prepared from 1 mg of total RNA using iScript (Bio-Rad)
according to manufacturer’s instructions, and then mixed with TaqMan Gene
Expression Master Mix and loaded onto a TaqMan Human Stem Cell Pluripotency
Low Density Array (TLDA, ThermoFisher). The arrays were run on a 7900HT
Real-Time PCR System (Applied Biosystems). The data were processed with RQ
Manager 1.2.1 software and relative expression (dC(t)) was calculated using
GAPDH as a control and used to compare across all cell lines using the statistical
programme GraphPad Prism 6. The hierarchical cluster analysis was performed by
Genesis51. All arrays were run at the SciLifeLab Genome facility (Uppsala, Sweden).
G-banding karyotype. Cultures of up to 70–80% conﬂuency were treated with
100 ngml 1 colcemide (KaryoMax colcemide Solution (10 mgml 1), Gibco)
overnight, and harvested using TrypLE (ThermoFisher). The cells were subse-
quently treated with freshly prepared hypotonic solution (75mM KCl, Sigma) for
30min at 37 C followed by a triple ﬁxator treatment (3:1 Methanol:Acetic acid,
both by Sigma) for 20min each. The dropping of ﬁxed cell suspension on cold
wet microscope slides was used to achieve metaphases, which were subsequently
processed using Trypsin (Sigma) and stained with Giemsa staining solution
(Sigma) for G-banding analysis52. For each sample, twenty metaphases were
analysed with IKAROS-software (MetaSystems). Description and speciﬁcation of
chromosomal aberrations was performed following guidelines from ISCN 2013.
SNP array and genotyping. SNP genotyping with Illumina HumanOmniEx-
pressExome-array version 8v1-2_A, encompassing 4964.000 single-nucleotide
polymorphism (SNP)-markers, was performed by the SNP&SEQ technology
Platform in Uppsala (www.genotyping.se), according to the manufacturer’s
instructions. Each of the four hPS cell lines (that is, H181, H207, HUES1 and K2C)
were analysed in three separate SNP-array experiments. Total DNA was extracted
from cell culture growth at 60-70% conﬂuence using the DNeasy Blood & Tissue
Kit (Cat. No. 69504, Qiagen). DNA concentration and purity was determined by
ultraviolet measurement. A ﬁrst analysis was performed after 2–5 passages of
growth for initial reference, and subsequently, two analyses were performed per cell
line after 16–21 passages in E8:VN or E8:IaI culture. The CN calls of the autosomal
chromosomes were illustrated using the Nexus software.
Copy-number analysis. Illumina output ﬁles were analysed using Nexus-
Copy-Number version 7.5 (BioDiscovery, CA, USA). Linear systematic correction
and the ‘SNP-FASST2 segmentation’ algorithm for CN-calling with default calling
parameters was applied. A ﬁrst CN analysis was performed on the autosomal
chromosomes for each cell line after 2–5 passages. Strict CN-calling criteria
(100% overlap of CN calls and Po0.05 in Nexus software) were applied. After this,
each of the four cell lines was grown to 16–21 passages, applying either the E8:IaI
or the E8:VN protocol. Subsequently, new CN-analyses using the same settings in
Nexus software was performed and the results were compared to the CN calls
from earlier. The number of shared CN calls between the early and later passages in
each of the four cell lines was used to quantify changes introduced during
culturing within each cell line under the E8:IaI and E8:VN protocols, respectively.
We used Wilcoxon rank-sum-test in the statistical software R v3 to test for
differences in the observed number of shared CN calls from the E8:IaI and
E8:VN protocols.
Clonal assay and MTT Tetrazolium assessment. The starting hPS cells were
pre-treated for 4–5 h with 10mM Y-27632 before harvesting them using TrypLE
(ThermoFisher). Brieﬂy, 1ml TrypLE was added to a pre-treated 6-well plate well
of hPS cells ready to passage. The cells were incubated with TrypLE for 8min
before removal and addition of 1ml E8 medium with 10 mM ROCKi, the cells were
harvested with a cell lifter. Cell clumps were broken down by pipetting and the
solution was passed through a 40 mm pore cell strainer to ensure single-cell
suspension (StemCell Technologies). The cells were then counted using the TCP
counter (Bio-Rad). After that the cells were diluted down to 100 cells in 10ml of E8
medium with 10mM ROCKi, mixed and seeded on VN coating or with IaI
supplementation in 100 ml per each of 100 wells (50 wells per 96-well plate) so as to
achieve approximately one cell per well. After two weeks the survival and
formation of colonies was assayed visually and through MTT assay. Brieﬂy, MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium was
dissolved in E8 medium at a ﬁnal concentration of 0.5mgml 1, the solution was
ﬁltered and added to the wells from the clonal assay and incubated at 37 C and 5%
CO2 for 3 h. After conﬁrming the staining of the existing colonies, the
MTT solution was removed and 20% SDS was added. The plates were incubated
O/N and the absorbance was read at 570 and 630 nm. This is a measure for viable
cells. Wells with more than one colony were removed from the ﬁnal result
summary.
Mass spectrometry analysis. Two samples of IaI working solution (puriﬁed
separately) were mixed with b-mercaptoethanol and run through a 12% acrylamide
SDS–PAGE denaturating gel. Band development was done through silver staining as
described previously53. The samples were in-gel digested with trypsin according to a
standard protocol and analysed by Liquid Chromatography Mass Spectrometry
(LC-Orbitrap MS/MS) at the MS Facility, SciLifeLab, Uppsala University. The
proteins were reduced, alkylated and in-gel digested by trypsin according to a
standard operating procedure. Thereafter the samples were dried and resolved in
15ml 0.1% FA (formic acid). The peptides were separated in reversed-phase on a
C18-column and electrosprayed on-line to an LTQ Velos Orbitrap mass
spectrometer (Thermo Finnigan). Tandem mass spectrometry was performed
applying CID. The database searches were performed using the Sequest algorithm,
embedded in Proteome Discoverer 2.1 (ThermoFisher), against human proteins in
the Swissprot database (2015). The search criteria for protein identiﬁcation were set
to at least two matching peptides of 95% conﬁdence level per protein.
Live imaging of hPS cell growth. Human PS cell lines were seeded onto 6-well
plates either as small clumps with GCDR or as single cells with TrypLE and 10 mM
Y-27632 (no pre-treatment). The imaging was performed with the oCelloscope
04C5 (Unisensor), placed inside a standard normoxic incubator. Pictures were
taken from the seeding point and then every 15min for up to 4 or 5 days (speciﬁed
for each video ﬁle). The imaging was performed using the Uniexplorer 3.2.0.3621
CRL3 software (Unisensor). The exported avi ﬁles were further edited using the
VideoPad Video Editor (Freeware).
Statistical analysis. Experiments were performed in at least three independent
experiments and in triplicate for each experiment. The data is presented as
mean±s.e.m. For the crystal violet cell analysis data multiple statistical analysis
was done using one-way ANOVA with Dunnett’s post-test, when applicable and
stated in the ﬁgure legends. Paired t-test was used to compare two speciﬁc samples
within groups, and the result is shown over a line connecting the two samples
within the graph. The Human Stem Cell Pluripotency Taqman Array data was
analysed using Two-way ANOVA and Sidak’s Multiple comparison’s test. All these
statistical analyses were done using GraphPad Prism version 5.00d for Mac
(GraphPad Software), and the data presented shows *Po0.05, **Po0.001 and
***Po0.001 unless otherwise speciﬁed. For the copy-number analysis a Wilcoxon
rank-sum-test in the statistical software R v3 was used.
Data availability. Data supporting the ﬁndings of this study are available within
the article and its Supplementary Information ﬁles and from the corresponding
author upon reasonable request. The SNP-array genotyping data have been
deposited in the NCBI-based Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/geo/) under the accession code GSE82103.
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